{"transactions":[{"id":1483276,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T21:02:09.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":69100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":15.92,"underlying":"Common Stock","underlying_shares":69100},"source":{"system":"sec-edgar","filing":"0000950170-24-072223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024072223/ownership.xml","form_type":"4"}},{"id":1483275,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T21:02:09.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":65900,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":15.48,"underlying":"Common Stock","underlying_shares":65900},"source":{"system":"sec-edgar","filing":"0000950170-24-072223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024072223/ownership.xml","form_type":"4"}},{"id":1483274,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T21:02:09.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":82000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":8.27,"underlying":"Common Stock","underlying_shares":82000},"source":{"system":"sec-edgar","filing":"0000950170-24-072223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024072223/ownership.xml","form_type":"4"}},{"id":1483273,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T21:02:09.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":82265,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":9.23,"underlying":"Common Stock","underlying_shares":82265},"source":{"system":"sec-edgar","filing":"0000950170-24-072223","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024072223/ownership.xml","form_type":"4"}},{"id":1483272,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-11T21:02:09.000Z","date":"2024-06-11","kind":"other","planned":false,"acquired":false,"shares":72261,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-072223","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024072223/ownership.xml","form_type":"4"}},{"id":1483271,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-11T21:02:09.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":72029,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration."}],"balance_after":72261,"source":{"system":"sec-edgar","filing":"0000950170-24-072223","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024072223/ownership.xml","form_type":"4"}},{"id":1483270,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-06-11T21:02:09.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":34157,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,394 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2024."}],"balance_after":144290,"source":{"system":"sec-edgar","filing":"0000950170-24-072223","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024072223/ownership.xml","form_type":"4"}},{"id":1633358,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-20T16:06:00.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":69100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024."}],"balance_after":69100,"derivative":{"exercise_price":15.92,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":69100},"source":{"system":"sec-edgar","filing":"0000950170-24-017085","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024017085/ownership.xml","form_type":"4"}},{"id":1633357,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-20T16:06:00.000Z","date":"2024-02-16","kind":"sale","planned":false,"acquired":false,"shares":2615,"price":15.6177,"value":40840.2855,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was to cover tax liabilities in the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.6172 to $15.6177, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":108739,"source":{"system":"sec-edgar","filing":"0000950170-24-017085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024017085/ownership.xml","form_type":"4"}},{"id":1633356,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-20T16:06:00.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":17275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was awarded 17,275 Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2025, February 15, 2026 and February 15, 2027."}],"balance_after":111354,"source":{"system":"sec-edgar","filing":"0000950170-24-017085","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024017085/ownership.xml","form_type":"4"}},{"id":1676191,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-01-18T16:15:48.000Z","date":"2024-01-16","kind":"sale","planned":false,"acquired":false,"shares":2435,"price":14.4697,"value":35233.7195,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock units."}],"balance_after":94079,"source":{"system":"sec-edgar","filing":"0000950170-24-005393","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017024005393/ownership.xml","form_type":"4"}},{"id":1710835,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-14T16:05:07.000Z","date":"2023-12-13","kind":"sale","planned":false,"acquired":false,"shares":2792,"price":15.3671,"value":42904.9432,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was to cover tax liabilities in the vesting of RSUs."}],"balance_after":96514,"source":{"system":"sec-edgar","filing":"0000950170-23-070382","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017023070382/ownership.xml","form_type":"4"}},{"id":1710834,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-12-14T16:05:07.000Z","date":"2023-12-12","kind":"grant","planned":false,"acquired":true,"shares":8244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 15, 2023, the Reporting Person was granted restricted stock units (\"RSUs\"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 15, 2023, the Reporting Person was granted restricted stock units (\"RSUs\"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 8,244 RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 434 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2023."}],"balance_after":99306,"source":{"system":"sec-edgar","filing":"0000950170-23-070382","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000095017023070382/ownership.xml","form_type":"4"}},{"id":1753101,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-10-31T16:11:28.000Z","date":"2023-10-30","kind":"sale","planned":false,"acquired":false,"shares":2360,"price":12.0176,"value":28361.536,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was to cover tax liabilities in the vesting of RSUs."}],"balance_after":90628,"source":{"system":"sec-edgar","filing":"0001209191-23-053939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919123053939/doc4.xml","form_type":"4"}},{"id":1753100,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-10-31T16:11:28.000Z","date":"2023-10-28","kind":"grant","planned":false,"acquired":true,"shares":8244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 15, 2023, the Reporting Person was granted restricted stock units (\"RSUs\"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 8,244 RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 15, 2023, the Reporting Person was granted restricted stock units (\"RSUs\"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 8,244 RSUs."}],"balance_after":92988,"source":{"system":"sec-edgar","filing":"0001209191-23-053939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919123053939/doc4.xml","form_type":"4"}},{"id":1765137,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-10-04T16:05:11.000Z","date":"2023-10-02","kind":"sale","planned":false,"acquired":false,"shares":2942,"price":12.68,"value":37304.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock units."}],"balance_after":84744,"source":{"system":"sec-edgar","filing":"0001209191-23-051886","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919123051886/doc4.xml","form_type":"4"}},{"id":1845066,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T16:45:31.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on the date of the Company's 2024 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":0.26,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001437749-23-018278","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000143774923018278/rdgdoc.xml","form_type":"4"}},{"id":1847690,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-06-21T16:05:30.000Z","date":"2023-06-16","kind":"sale","planned":false,"acquired":false,"shares":1655,"price":14.4018,"value":23834.979,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,196 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2023."}],"balance_after":87686,"source":{"system":"sec-edgar","filing":"0001209191-23-038756","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919123038756/doc4.xml","form_type":"4"}},{"id":2007238,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-17T16:07:38.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":65900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2023."}],"balance_after":65900,"derivative":{"exercise_price":15.48,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":65900},"source":{"system":"sec-edgar","filing":"0001209191-23-010506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919123010506/doc4.xml","form_type":"4"}},{"id":2007237,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-17T16:07:38.000Z","date":"2023-02-16","kind":"sale","acquired":false,"shares":971,"price":15.099,"value":14661.129,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was to cover tax liabilities in the vesting of restricted stock."}],"balance_after":88145,"source":{"system":"sec-edgar","filing":"0001209191-23-010506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919123010506/doc4.xml","form_type":"4"}},{"id":2007236,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-17T16:07:38.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":16488,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was awarded 16,488 Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2024, February 15, 2025 and February 15, 2026."}],"balance_after":89116,"source":{"system":"sec-edgar","filing":"0001209191-23-010506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919123010506/doc4.xml","form_type":"4"}},{"id":2050695,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-01-19T16:05:51.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":2403,"price":21.2413,"value":51042.8439,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 734 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2022."}],"balance_after":72628,"source":{"system":"sec-edgar","filing":"0001209191-23-003998","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919123003998/doc4.xml","form_type":"4"}},{"id":2142079,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-10-05T16:05:26.000Z","date":"2022-10-03","kind":"sale","acquired":false,"shares":2587,"price":18.73,"value":48454.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock."}],"balance_after":74297,"source":{"system":"sec-edgar","filing":"0001209191-22-052717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919122052717/doc4.xml","form_type":"4"}},{"id":2221911,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T19:02:21.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on the date of the Company's 2023 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":1.82,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001583648-22-000048","document":"wf-form4_165611172543156.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000158364822000048/wf-form4_165611172543156.xml","form_type":"4"}},{"id":2225259,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-06-21T16:37:17.000Z","date":"2022-06-16","kind":"sale","acquired":false,"shares":1768,"price":10.75,"value":19006.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,862 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2022."}],"balance_after":76884,"source":{"system":"sec-edgar","filing":"0001209191-22-038432","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919122038432/doc4.xml","form_type":"4"}},{"id":2385113,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-18T17:01:21.000Z","date":"2022-02-16","kind":"sale","acquired":false,"shares":984,"price":9.05,"value":8905.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock."}],"balance_after":76790,"source":{"system":"sec-edgar","filing":"0001209191-22-011361","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919122011361/doc4.xml","form_type":"4"}},{"id":2430257,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-20T17:00:28.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":82000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan.  The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022."}],"balance_after":82000,"derivative":{"exercise_price":8.27,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":82000},"source":{"system":"sec-edgar","filing":"0001209191-22-004076","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919122004076/doc4.xml","form_type":"4"}},{"id":2430256,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-01-20T17:00:28.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was awarded 20,500 Restricted Stock Units (\"RSUs\"). Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock. The RSUs shall vest in three (3) equal annual installments on each of January 15, 2023, January 15, 2024 and January 15, 2025."}],"balance_after":77774,"source":{"system":"sec-edgar","filing":"0001209191-22-004076","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919122004076/doc4.xml","form_type":"4"}},{"id":2465767,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-17T16:05:18.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":82265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option was issued pursuant to the 2017 Plan.  The option shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to  continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through each vesting date."}],"balance_after":82265,"derivative":{"exercise_price":9.23,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":82265},"source":{"system":"sec-edgar","filing":"0001209191-21-070232","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919121070232/doc4.xml","form_type":"4"}},{"id":2465766,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-12-17T16:05:18.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":11100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was awarded 11,100 Restricted Stock Units (\"RSUs\")  under the Issuer's 2017 Stock Option and Incentive Plan (the \"2017 Plan\"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through such dates. The RSUs may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 145 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 12, 2021."}],"balance_after":57274,"source":{"system":"sec-edgar","filing":"0001209191-21-070232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919121070232/doc4.xml","form_type":"4"}},{"id":2547059,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-06T16:00:18.000Z","date":"2021-10-04","kind":"sale","acquired":false,"shares":2659,"price":33.17,"value":88199.03,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 302 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on May 14, 2021."}],"balance_after":46029,"source":{"system":"sec-edgar","filing":"0001209191-21-059804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919121059804/doc4.xml","form_type":"4"}},{"id":2651560,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-29T17:38:32.000Z","date":"2021-06-25","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on the date of the Company's 2022 annual stockholders meeting, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":4,"expiration_date":"2031-06-25","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001562180-21-004564","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000156218021004564/primarydocument.xml","form_type":"4"}},{"id":2849651,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T19:00:16.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":49900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan.  The option shall vest in equal monthly installments over four years, beginning on March 16, 2021."}],"balance_after":49900,"derivative":{"exercise_price":47.79,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":49900},"source":{"system":"sec-edgar","filing":"0001209191-21-012114","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919121012114/doc4.xml","form_type":"4"}},{"id":2849650,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-18T19:00:16.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":11100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person was awarded 11,100 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2022, February 15, 2023, February 15, 2024 and February 15, 2025, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":48386,"source":{"system":"sec-edgar","filing":"0001209191-21-012114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919121012114/doc4.xml","form_type":"4"}},{"id":2849649,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-18T19:00:16.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":132,"price":48.87,"value":6450.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock."}],"balance_after":37286,"source":{"system":"sec-edgar","filing":"0001209191-21-012114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919121012114/doc4.xml","form_type":"4"}},{"id":2948426,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2020-12-11T16:10:07.000Z","date":"2020-12-09","kind":"exercise","acquired":false,"shares":207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on October 1, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":147096,"derivative":{"exercise_price":34.43,"expiration_date":"2029-10-14","underlying":"Common Stock","underlying_shares":207},"source":{"system":"sec-edgar","filing":"0001209191-20-062920","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919120062920/doc4.xml","form_type":"4"}},{"id":2948425,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-12-11T16:10:07.000Z","date":"2020-12-09","kind":"exercise","acquired":true,"shares":207,"price":34.43,"value":7127.01,"ownership":{"direct":true},"balance_after":37418,"source":{"system":"sec-edgar","filing":"0001209191-20-062920","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919120062920/doc4.xml","form_type":"4"}},{"id":2974922,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2020-11-18T19:31:24.000Z","date":"2020-11-16","kind":"exercise","acquired":false,"shares":2697,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on October 1, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":147303,"derivative":{"exercise_price":34.43,"expiration_date":"2029-10-14","underlying":"Common Stock","underlying_shares":2697},"source":{"system":"sec-edgar","filing":"0001209191-20-059256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919120059256/doc4.xml","form_type":"4"}},{"id":2974921,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-11-18T19:31:24.000Z","date":"2020-11-16","kind":"exercise","acquired":true,"shares":2697,"price":34.43,"value":92857.71,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 386 shares acquired under the Issuer's 2017 Employee Stock Purchase Plan on November 14, 2020."}],"balance_after":37211,"source":{"system":"sec-edgar","filing":"0001209191-20-059256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919120059256/doc4.xml","form_type":"4"}},{"id":3011567,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-10-06T16:00:08.000Z","date":"2020-10-02","kind":"tax_withholding","acquired":false,"shares":2632,"price":51.1467,"value":134618.1144,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was to cover tax liabilities in the vesting of restricted stock."}],"balance_after":34128,"source":{"system":"sec-edgar","filing":"0001209191-20-053994","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919120053994/doc4.xml","form_type":"4"}},{"id":3099670,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-25T16:46:06.000Z","date":"2020-06-23","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on June 23, 2021, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":40000,"derivative":{"exercise_price":3.27,"expiration_date":"2030-06-23","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001562180-20-004692","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000156218020004692/primarydocument.xml","form_type":"4"}},{"id":3259173,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-20T16:10:15.000Z","date":"2020-02-18","kind":"grant","acquired":false,"shares":10520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option award was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments over a 4-year period following the vesting commencement date of 2/18/2020, subject to continued service through such dates."}],"balance_after":10520,"derivative":{"exercise_price":54.87,"expiration_date":"2030-02-17","underlying":"Common Stock","underlying_shares":10520},"source":{"system":"sec-edgar","filing":"0001209191-20-011041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919120011041/doc4.xml","form_type":"4"}},{"id":3259172,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-02-20T16:10:15.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":1760,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person was awarded 1,760 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2021, February 15, 2022, February 15, 2023 and February 15, 2024, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":36760,"source":{"system":"sec-edgar","filing":"0001209191-20-011041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919120011041/doc4.xml","form_type":"4"}},{"id":3300043,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-28T16:22:45.000Z","date":"2020-01-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on January 25, 2021, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":20000,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-20-000625","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000156218020000625/primarydocument.xml","form_type":"4"}},{"id":3391715,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-17T16:35:04.000Z","date":"2019-10-15","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on October 1, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":150000,"derivative":{"exercise_price":34.43,"expiration_date":"2029-10-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-19-053427","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919119053427/doc4.xml","form_type":"4"}},{"id":3391714,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-10-17T16:35:04.000Z","date":"2019-10-15","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was awarded 35,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in four (4) equal annual installments beginning on October 1, 2020, subject to the reporting person's continuous service with the Company through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":35000,"source":{"system":"sec-edgar","filing":"0001209191-19-053427","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000120919119053427/doc4.xml","form_type":"4"}},{"id":3449687,"issuer":{"id":85102,"kind":"organization","name":"LUMOS PHARMA, INC.","symbol":"(LUMO)"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T18:39:58.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":13889,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program.  In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date."}],"balance_after":13889,"derivative":{"exercise_price":1.77,"expiration_date":"2026-07-31","underlying":"Common Stock","underlying_shares":13889},"source":{"system":"sec-edgar","filing":"0001126234-19-000106","document":"wf-form4_156478558165297.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623419000106/wf-form4_156478558165297.xml","form_type":"4"}},{"id":3449686,"issuer":{"id":85102,"kind":"organization","name":"LUMOS PHARMA, INC.","symbol":"(LUMO)"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T18:39:58.000Z","date":"2019-07-31","kind":"disposition_to_issuer","acquired":false,"shares":27777,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program.  In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option provided that one hundred percent (100%) of the shares would vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date."}],"balance_after":0,"derivative":{"exercise_price":5.33,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":27777},"source":{"system":"sec-edgar","filing":"0001126234-19-000106","document":"wf-form4_156478558165297.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623419000106/wf-form4_156478558165297.xml","form_type":"4"}},{"id":3449685,"issuer":{"id":85102,"kind":"organization","name":"LUMOS PHARMA, INC.","symbol":"(LUMO)"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T18:39:58.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":18506,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program.  In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests as to 50% on the second anniversary of grant date and the remaining 50% on the third anniversary of grant date."}],"balance_after":18506,"derivative":{"exercise_price":1.77,"expiration_date":"2026-07-31","underlying":"Common Stock","underlying_shares":18506},"source":{"system":"sec-edgar","filing":"0001126234-19-000106","document":"wf-form4_156478558165297.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623419000106/wf-form4_156478558165297.xml","form_type":"4"}},{"id":3449684,"issuer":{"id":85102,"kind":"organization","name":"LUMOS PHARMA, INC.","symbol":"(LUMO)"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T18:39:58.000Z","date":"2019-07-31","kind":"grant","acquired":true,"shares":13218,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program.  In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 50% on the first anniversary of grant date and the remaining 50% on the second anniversary of grant date."}],"balance_after":13218,"derivative":{"exercise_price":1.77,"expiration_date":"2026-07-31","underlying":"Common Stock","underlying_shares":13218},"source":{"system":"sec-edgar","filing":"0001126234-19-000106","document":"wf-form4_156478558165297.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623419000106/wf-form4_156478558165297.xml","form_type":"4"}},{"id":3449683,"issuer":{"id":85102,"kind":"organization","name":"LUMOS PHARMA, INC.","symbol":"(LUMO)"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T18:39:58.000Z","date":"2019-07-31","kind":"disposition_to_issuer","acquired":false,"shares":63447,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On July 31, 2019, the issuer cancelled this option grant pursuant to the issuer's option exchange program.  In exchange, for every two cancelled options, the reporting person received a replacement option having an exercise price of $1.77 per share."}],"balance_after":0,"derivative":{"exercise_price":4.56,"exercise_date":"2019-04-30","expiration_date":"2028-04-29","underlying":"Common Stock","underlying_shares":63447},"source":{"system":"sec-edgar","filing":"0001126234-19-000106","document":"wf-form4_156478558165297.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623419000106/wf-form4_156478558165297.xml","form_type":"4"}},{"id":3518310,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-20T16:13:29.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in forty-eight (48) equal monthly installments on the 16th day of each month, with the first tranche vesting on June 16, 2019, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. Amended and Restated 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":15000,"derivative":{"exercise_price":1.06,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-014141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000089924319014141/doc4.xml","form_type":"4"}},{"id":3527929,"issuer":{"id":85102,"kind":"organization","name":"LUMOS PHARMA, INC.","symbol":"(LUMO)"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-14T17:33:53.000Z","date":"2019-05-10","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan, as amended (the \"Plan\").  One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date.  The option expires ten years after the date of grant."}],"balance_after":25000,"derivative":{"exercise_price":1.69,"expiration_date":"2029-05-09","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001126234-19-000059","document":"wf-form4_155786961881847.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623419000059/wf-form4_155786961881847.xml","form_type":"4"}},{"id":3683723,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-29T17:46:04.000Z","date":"2019-01-25","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.74,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-19-000580","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000156218019000580/primarydocument.xml","form_type":"4"}},{"id":3782871,"issuer":{"id":4452,"kind":"organization","name":"PALVELLA THERAPEUTICS, INC.","symbol":"PVLA"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-10-25T17:21:02.000Z","date":"2018-10-24","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest as to 100% of the underlying shares on October 24, 2019, subject to the Reporting Person's continued service as a director through the vesting date."}],"balance_after":30000,"derivative":{"exercise_price":4.46,"expiration_date":"2028-10-24","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001562180-18-004281","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000156218018004281/primarydocument.xml","form_type":"4"}},{"id":3903225,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-06-06T18:00:37.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":124000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4) of the option vested on June 5, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow June 5, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":124000,"derivative":{"exercise_price":0.468,"expiration_date":"2028-06-05","underlying":"Common Stock","underlying_shares":124000},"source":{"system":"sec-edgar","filing":"0000899243-18-015297","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000089924318015297/doc4.xml","form_type":"4"}},{"id":3917312,"issuer":{"id":85102,"kind":"organization","name":"LUMOS PHARMA, INC.","symbol":"(LUMO)"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-25T18:00:38.000Z","date":"2018-05-23","kind":"grant","acquired":true,"shares":27777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2009 Equity Incentive Plan (the \"Plan\").  One hundred percent (100%) of the shares shall vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the first Annual Meeting following the date of grant, in each case subject to the Reporting Person's continuous service as of such date.  The option expires ten years after the date of grant."}],"balance_after":27777,"derivative":{"exercise_price":5.33,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":27777},"source":{"system":"sec-edgar","filing":"0001126234-18-000099","document":"wf-form4_152728562008093.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1126234/000112623418000099/wf-form4_152728562008093.xml","form_type":"4"}},{"id":3968358,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Warrant (right to buy)","published_at":"2018-04-05T20:07:29.000Z","date":"2018-04-03","kind":"purchase","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit.  Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share."}],"balance_after":20000,"derivative":{"exercise_price":0.75,"exercise_date":"2018-04-03","expiration_date":"2023-04-03","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-18-009608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000089924318009608/doc4.xml","form_type":"4"}},{"id":3968357,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series A Warrant (right to buy)","published_at":"2018-04-05T20:07:29.000Z","date":"2018-04-03","kind":"purchase","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit.  Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share."}],"balance_after":20000,"derivative":{"exercise_price":0.65,"exercise_date":"2018-04-03","expiration_date":"2018-10-03","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-18-009608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000089924318009608/doc4.xml","form_type":"4"}},{"id":3968356,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-04-05T20:07:29.000Z","date":"2018-04-03","kind":"purchase","acquired":true,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The reported securities were included within 20,000 Units purchased by the reporting person for $0.65 per Unit.  Each Unit consisted of one share of common stock, one Series A Warrant to purchase one share of common stock at an exercise price of $0.65 per share, and one Series B Warrant to purchase one share of common stock at an exercise price of $0.75 per share."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0000899243-18-009608","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000089924318009608/doc4.xml","form_type":"4"}},{"id":3969603,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-04-04T16:39:09.000Z","date":"2018-04-03","kind":"sale","acquired":false,"shares":900,"price":39.04,"value":35136.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.80 to $39.59 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":68767,"source":{"system":"sec-edgar","filing":"0001179110-18-005397","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911018005397/edgar.xml","form_type":"4"}},{"id":3969602,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-04-04T16:39:09.000Z","date":"2018-04-03","kind":"sale","acquired":false,"shares":3700,"price":38.28,"value":141636.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.71 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":69667,"source":{"system":"sec-edgar","filing":"0001179110-18-005397","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911018005397/edgar.xml","form_type":"4"}},{"id":4107252,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-04T19:02:55.000Z","date":"2018-01-03","kind":"sale","acquired":false,"shares":2033,"price":43.33,"value":88089.89,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.91 to $43.50 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":73367,"source":{"system":"sec-edgar","filing":"0001179110-18-000545","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911018000545/edgar.xml","form_type":"4"}},{"id":4107251,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-04T19:02:55.000Z","date":"2018-01-03","kind":"sale","acquired":false,"shares":2300,"price":42.4,"value":97520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.89 to $42.86 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":75400,"source":{"system":"sec-edgar","filing":"0001179110-18-000545","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911018000545/edgar.xml","form_type":"4"}},{"id":4107250,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-04T19:02:55.000Z","date":"2018-01-03","kind":"sale","acquired":false,"shares":300,"price":40.86,"value":12258.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.85 to $40.87 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":77700,"source":{"system":"sec-edgar","filing":"0001179110-18-000545","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911018000545/edgar.xml","form_type":"4"}},{"id":4209280,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-09-14T17:02:55.000Z","date":"2017-09-12","kind":"sale","acquired":false,"shares":150,"price":39.91,"value":5986.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.87 to $39.93 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":78000,"source":{"system":"sec-edgar","filing":"0001179110-17-012288","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017012288/edgar.xml","form_type":"4"}},{"id":4209279,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-09-14T17:02:55.000Z","date":"2017-09-12","kind":"sale","acquired":false,"shares":1600,"price":39.24,"value":62784.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.82 to $39.75 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":78150,"source":{"system":"sec-edgar","filing":"0001179110-17-012288","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017012288/edgar.xml","form_type":"4"}},{"id":4209278,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-09-14T17:02:55.000Z","date":"2017-09-12","kind":"sale","acquired":false,"shares":16650,"price":38.32,"value":638028.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.81 to $38.80 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":79750,"source":{"system":"sec-edgar","filing":"0001179110-17-012288","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017012288/edgar.xml","form_type":"4"}},{"id":4260810,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2017-07-07T16:55:22.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options of registrant's common stock vest in equal quarterly installments over the first four years after the grant."}],"balance_after":0,"derivative":{"exercise_price":7.12,"expiration_date":"2022-12-12","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001179110-17-010224","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017010224/edgar.xml","form_type":"4"}},{"id":4260809,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-07-07T16:55:22.000Z","date":"2017-07-05","kind":"sale","acquired":false,"shares":16000,"price":32,"value":512000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":96400,"source":{"system":"sec-edgar","filing":"0001179110-17-010224","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017010224/edgar.xml","form_type":"4"}},{"id":4260808,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-07-07T16:55:22.000Z","date":"2017-07-05","kind":"exercise","acquired":true,"shares":8000,"price":7.12,"value":56960.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":112400,"source":{"system":"sec-edgar","filing":"0001179110-17-010224","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017010224/edgar.xml","form_type":"4"}},{"id":4374732,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-22T18:51:16.000Z","date":"2017-03-20","kind":"grant","acquired":true,"shares":4400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4) of the option vests on March 20, 2018 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting for each of the next thirty-six (36) months that follow March 20, 2018, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":4400,"derivative":{"exercise_price":2.78,"expiration_date":"2027-03-20","underlying":"Common Stock","underlying_shares":4400},"source":{"system":"sec-edgar","filing":"0000899243-17-008412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000089924317008412/doc4.xml","form_type":"4"}},{"id":4386155,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2017-03-14T18:15:56.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":47300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2017."}],"balance_after":47300,"derivative":{"exercise_price":30.17,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":47300},"source":{"system":"sec-edgar","filing":"0001179110-17-004589","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017004589/edgar.xml","form_type":"4"}},{"id":4386154,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-03-14T18:15:56.000Z","date":"2017-03-02","kind":"grant","acquired":true,"shares":7900,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":104400,"source":{"system":"sec-edgar","filing":"0001179110-17-004589","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017004589/edgar.xml","form_type":"4"}},{"id":4496286,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-06T17:12:12.000Z","date":"2017-01-04","kind":"sale","acquired":false,"shares":1600,"price":27.62,"value":44192.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.45 to $27.79, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":96500,"source":{"system":"sec-edgar","filing":"0001179110-17-000681","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017000681/edgar.xml","form_type":"4"}},{"id":4496285,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Medical Officer"}}],"security":"Common Stock","published_at":"2017-01-06T17:12:12.000Z","date":"2017-01-04","kind":"sale","acquired":false,"shares":400,"price":26.81,"value":10724.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.42 to $27.32, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":98100,"source":{"system":"sec-edgar","filing":"0001179110-17-000681","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000117911017000681/edgar.xml","form_type":"4"}},{"id":4590006,"issuer":{"id":8249,"kind":"organization","name":"Pulmatrix, Inc."},"owners":[{"id":90046,"kind":"person","name":"Sherman Matthew L","position":1,"cik":"0001325710","reported_name":"Sherman Matthew L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-03T11:05:17.000Z","date":"2016-09-29","kind":"grant","acquired":true,"shares":8800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4) of the option vests on September 29, 2017 and the remainder vests in thirty-six (36) equal monthly installments with 2.083% vesting on the last day of each of the next thirty-six (36) months that follow September 29, 2017, provided that the reporting person is providing services to the Issuer on the applicable vesting date and subject to the terms and conditions of the Pulmatrix, Inc. 2013 Employee, Director and Consultant Equity Incentive Plan."}],"balance_after":8800,"derivative":{"exercise_price":1.55,"expiration_date":"2026-09-29","underlying":"Common Stock","underlying_shares":8800},"source":{"system":"sec-edgar","filing":"0000899243-16-030535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1325710/000089924316030535/doc4.xml","form_type":"4"}}]}